Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Conditions
Interventions
Darbepoetin alfa
Placebo
Locations
566
United States
Research Site
Anniston, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Anchorage, Alaska, United States
Research Site
Tucson, Arizona, United States
Research Site
Fayetteville, Arkansas, United States
Research Site
Hot Springs, Arkansas, United States
Start Date
July 17, 2009
Primary Completion Date
June 7, 2017
Completion Date
June 7, 2017
Last Updated
November 30, 2022
NCT06594926
NCT07489378
NCT05671510
NCT07446322
NCT07547774
NCT07040891
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions